Licata & Tyrrell P.C.
Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.
Acumen Pharmaceuticals, Inc. Merck Sharp & Dohme Corp.
C C C A C C A C A C C A A A
C07K C07K C07K A61K C07K C07K A61P C07K A61P C07K C07K A61K A61P A61K
additional additional additional additional inventional additional inventional additional inventional additional additional inventional inventional inventional
Renee C. Fubao William F. Ningyan Min Wei-Qin Weirong Alexander Franz F. Paul J.
Gaspar Wang Goure Zhang Xu Zhao Wang McCampbell Hefti Shughrue